Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Japan Embassy Granted First In-Person Visit to Detained Astellas Employee
The Japanese embassy in China has been granted its first in-person consular access to an employee of Astellas Pharma detained by Chinese authorities earlier this year on the suspicion of espionage, it was learned on July 21. Since March, when…
To read the full story
Related Article
- Astellas Employee Did Not Appeal, Prison Sentence Finalized in China
July 29, 2025
- Astellas Employee Won’t Appeal China Espionage Sentence
July 22, 2025
- Astellas Employee Sentenced to 3.5 Years in China for Spying
July 17, 2025
- Verdict Due July 16 for Astellas Employee Detained in China
July 14, 2025
- Japan Will Persistently Urge China to Release Detained Astellas Employee: Govt
April 12, 2024
- 1 Year on, China Mulling Potential Indictment of Detained Astellas Employee
March 22, 2024
- Japan Ambassador Meets Astellas Employee Detained in China
November 29, 2023
- China Formally Arrests Astellas Employee, Japan Urges Immediate Release
October 20, 2023
- China to Soon Decide Whether to Arrest Detained Japanese Astellas Employee
September 21, 2023
- China Envoy Says Spying Allegations of Astellas Employee Becoming Certain
April 10, 2023
- Japanese Embassy Official Meets Astellas Employee Detained in China
April 5, 2023
- Japanese Foreign Minister Demands Release of Man Detained in China
April 3, 2023
- Japan’s Foreign Minister Likely to Visit China Soon, Demand Citizen’s Release
March 29, 2023
- Japan Industry Frets Fate of Astellas Worker Held in China for Espionage Allegation
March 28, 2023
- Japanese Man Detained in China was Astellas Employee
March 27, 2023
REGULATORY
- Council Floats 9.6% Growth Target for Japan’s On-Patent Drug Market
March 11, 2026
- MHLW Approves Towa Generics for Revolade, Vimpat
March 11, 2026
- Panel Clears Zolgensma Intrathecal Form to Expand Use in Older SMA Patients
March 10, 2026
- Japan Approves MSD’s HIV Combo Idvynso
March 9, 2026
- MHLW Updates Elective Care LLP List; Target Products Down Sharply to 776
March 9, 2026
International regulators are increasingly moving away from comparative efficacy studies (CES) in biosimilar development — long considered a default requirement…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…